PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis

Leukemia

Volumn 28, Issue 3, 2014, Pages 629-641

  Berger, A ^a   Hoelbl Kovacic, A ^a   Bourgeais, J ^b   Hoefling, L ^a   Warsch, W ^a   Grundschober, E ^a   Uras, I Z ^a   Menzl, I ^a   Putz, E M ^a   Hoermann, G ^c   Schuster, C ^d   Fajmann, S ^a   Leitner, E ^e   Kubicek, S ^e   Moriggl, R ^f   Gouilleux, F ^b   Sexl, V ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b UNIVERSITÉ DE TOURS   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BCR ABL; Nuclear translocation; Serine phosphorylation; STAT5

Indexed keywords

BCR ABL PROTEIN; P21 ACTIVATED KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SERINE; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; LEUKEMIA; MICE; MICE, INBRED C57BL; P21-ACTIVATED KINASES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; SERINE; STAT5 TRANSCRIPTION FACTOR;

EID: 84895831090     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.351     Document Type: Article

References (55)

1. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-1142.
2. Turkson J, Jove R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626.
3. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffé M et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
4. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
5. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
6. Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119: 3539-3549.
7. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000; 6: 693-704.
8. Ilaria Jr RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271: 31704-31710.
9. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-Transformed cells. Blood 2000; 95: 2118-2125.
10. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107: 4898-4906.
11. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010; 2: 98-110.
12. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 2013; 4: 437-444.
13. Leonard WJ, O'Shea JJ. Jaks and STATs: Biological implications. Ann Rev Immunol 1998; 16: 293-322.
14. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820.
15. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCRAbl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159: 4720-4728.
16. Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell 2005; 7: 87-99.
17. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-2637.
18. Wen Z, Zhong Z, Darnell Jr JE. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
19. Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA et al. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 2001; 183: 151-163.
20. Beuvink I, Hess D, Flotow H, Hofsteenge J, Groner B, Hynes NE. Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity. J Biol Chem 2000; 275: 10247-10255.
21. Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K et al. Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol 2009; 183: 2286-2293.
22. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 2003; 19: 793-802.
23. Gough DJ, Corlett A, Schlessinger K,Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324: 1713-1716.
24. Aziz MH, Manoharan HT, Sand JM, Verma AK. Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Mol Carcinog 2007; 46: 646-653.
25. Qin HR, Kim H-J, Kim J-Y, Hurt EM, Klarmann GJ, Kawasaki BT et al. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 2008; 68: 7736-7741.
26. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765-3770.
27. Friedbichler K, Kerenyi MA, Kovacic B, Li G, Hoelbl A, Yahiaoui S et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 2010; 116: 1548-1558.
28. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
29. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 2004; 24: 8037-8047.
30. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10: 77-87.
31. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/ abl-induced transformation are independent of stat5. Blood 2000; 96: 2277-2283.
32. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with ''mini-extracts'', prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
33. Schuster B, Hendry L, Byers H, Lynham SF, Ward MA, John S. Purification and identification of the STAT5 protease in myeloid cells. Biochem J 2007; 404: 81-87.
34. Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 2007; 109: 1678-1686.
35. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 2013; 38: 250-262.
36. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
37. Menet CJ, Rompaey L, Van, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem 2013; 52: 153-223.
38. Krause DS, Van Etten RA. Right on target: Eradicating leukemic stem cells. Trends Mol Medi 2007; 13: 470-481.
39. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Basecke J et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25: 1080-1094.
40. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner K-U et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature chemical biology 2012; 8: 285-293.
41. Mallette FA, Gaumont-Leclerc M-F, Huot G, Ferbeyre G. Myc down-regulation as a mechanism to activate the Rb pathway in STAT5A-induced senescence. J Biol Chem 2007; 282: 34938-34944.
42. Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan A-S et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 2012; 3: 1669-1687.
43. Warsch W, Grundschober E, Sexl V. Adding a new facet to STAT5 in CML: Multitasking for leukemic cells. Cell cycle 2013; 12: 1813-1814.
44. McBride KM, Banninger G, McDonald C, Reich NC. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-Alpha. EMBO J 2002; 21: 1754-1763.
45. Melen K, Kinnunen L, Julkunen I. Arginine/lysine-rich structural element is involved in interferon-induced nuclear import of STATs. J Biol Chem 2001; 276: 16447-16455.
46. Meyer T, Begitt A, Lö dige I, Van Rossum M, Vinkemeier U. Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J 2002; 21: 344-354.
47. Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H et al. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABLpositive cells. Oncogene 2013; 32: 3587-3597.
48. Clark DE, Williams CC, Duplessis TT, Moring KL, Notwick AR, Long W et al. ERBB4/ HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. J Biol Chem 2005; 280: 24175-24180.
49. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003; 162: 281-291.
50. Lim L, Manser E, Leung T, Hall C. Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. Eur J Biochem 1996; 242: 171-185.
51. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009; 28: 51-63.
52. Thomas EK, Cancelas JA, Zheng Y, Williams DA. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia 2008; 22: 898-904.
53. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Ja?ra˚s M, Puram RV et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 2013; 24: 45-58.
54. Kumar R, Gururaj AE, Barnes CJ. p21-Activated kinases in cancer. Nat Rev Cancer 2006; 6: 459-471.
55. Wang R-A, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006; 25: 2931-2936..